Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II cross-over study of intravenous morphine + naloxone ratios
2011-005903-34Phase 2Completed
- Sponsor
- G.L. Pharma
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of morphine and naloxone in opioid use disorder (OUD) (2 arms), sponsored by G.L. Pharma. Primary endpoint: Opioid withdrawal signs and symptoms. Started Mar 2012; status: completed.
02
Drugs
morphinenaloxone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on 2011-005903-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005903-34.